Intervention Review

You have free access to this content

Vaccines for preventing malaria (pre-erythrocytic)

  1. Patricia M Graves1,*,
  2. Hellen Gelband2

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 13 JUN 2006

DOI: 10.1002/14651858.CD006198

Database Title

Additional Information

How to Cite

Graves PM, Gelband H. Vaccines for preventing malaria (pre-erythrocytic). Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006198. DOI: 10.1002/14651858.CD006198.

Author Information

  1. 1

    EpiVec Consulting, Atlanta, Georgia, USA

  2. 2

    Resources for the Future, Washington, DC, USA

*Patricia M Graves, EpiVec Consulting, Atlanta, Georgia, GA 30341, USA. epivec@comcast.net. pmgraves@aol.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (60K)Standard (307K)Full (443K)
[Analysis 1.1]
Analysis 1.1. Comparison 1 CS-NANP vaccine versus control, Outcome 1 New malaria infection.
[Analysis 2.1]
Analysis 2.1. Comparison 2 CS-102 vaccine versus control, Outcome 1 Nausea.
[Analysis 2.2]
Analysis 2.2. Comparison 2 CS-102 vaccine versus control, Outcome 2 Fever.
[Analysis 2.3]
Analysis 2.3. Comparison 2 CS-102 vaccine versus control, Outcome 3 Malaise.
[Analysis 3.1]
Analysis 3.1. Comparison 3 RTS,S vaccine versus control, Outcome 1 New infection: by type of challenge.
[Analysis 3.2]
Analysis 3.2. Comparison 3 RTS,S vaccine versus control, Outcome 2 New infection: by age group.
[Analysis 3.3]
Analysis 3.3. Comparison 3 RTS,S vaccine versus control, Outcome 3 Clinical malaria episodes.
[Analysis 3.4]
Analysis 3.4. Comparison 3 RTS,S vaccine versus control, Outcome 4 Clinical malaria episodes: by year.
[Analysis 3.5]
Analysis 3.5. Comparison 3 RTS,S vaccine versus control, Outcome 5 Severe malaria.
[Analysis 3.6]
Analysis 3.6. Comparison 3 RTS,S vaccine versus control, Outcome 6 Malaria requiring admission.
[Analysis 3.7]
Analysis 3.7. Comparison 3 RTS,S vaccine versus control, Outcome 7 Admission to hospital for any cause.
[Analysis 3.8]
Analysis 3.8. Comparison 3 RTS,S vaccine versus control, Outcome 8 Prevalence of parasitaemia.
[Analysis 3.9]
Analysis 3.9. Comparison 3 RTS,S vaccine versus control, Outcome 9 Anaemia (packed cell volume < 25%).
[Analysis 3.10]
Analysis 3.10. Comparison 3 RTS,S vaccine versus control, Outcome 10 Adverse events.
[Analysis 3.11]
Analysis 3.11. Comparison 3 RTS,S vaccine versus control, Outcome 11 Severe adverse events.
[Analysis 4.1]
Analysis 4.1. Comparison 4 ME-TRAP vaccine versus control, Outcome 1 New malaria infection.
[Analysis 4.2]
Analysis 4.2. Comparison 4 ME-TRAP vaccine versus control, Outcome 2 Clinical malaria episodes.
[Analysis 4.3]
Analysis 4.3. Comparison 4 ME-TRAP vaccine versus control, Outcome 3 Density of Plasmodium falciparum.
[Analysis 4.4]
Analysis 4.4. Comparison 4 ME-TRAP vaccine versus control, Outcome 4 Mean packed cell volume.
[Analysis 4.5]
Analysis 4.5. Comparison 4 ME-TRAP vaccine versus control, Outcome 5 Adverse events.
View Full Article (HTML) Summary (60K)Standard (307K)Full (443K)